Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $674000.0.

  • Bicycle Therapeutics' Capital Expenditures rose 5494.25% to $674000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 13355.12%. This contributed to the annual value of $1.2 million for FY2024, which is 5783.54% down from last year.
  • As of Q3 2025, Bicycle Therapeutics' Capital Expenditures stood at $674000.0, which was up 5494.25% from $498000.0 recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Capital Expenditures peaked at $9.8 million during Q2 2022, and registered a low of $12000.0 during Q1 2024.
  • Moreover, its 5-year median value for Capital Expenditures was $502000.0 (2023), whereas its average is $1.4 million.
  • In the last 5 years, Bicycle Therapeutics' Capital Expenditures soared by 563040.94% in 2022 and then tumbled by 9942.83% in 2024.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Capital Expenditures stood at $1.1 million in 2021, then soared by 35.71% to $1.4 million in 2022, then crashed by 96.48% to $51000.0 in 2023, then surged by 621.57% to $368000.0 in 2024, then soared by 83.15% to $674000.0 in 2025.
  • Its Capital Expenditures stands at $674000.0 for Q3 2025, versus $498000.0 for Q2 2025 and $604000.0 for Q1 2025.